The Pharmalot View

The Pharmalot View Ed Silverman

STAT Plus: The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous

The Pharmalot View Ed Silverman

STAT Plus: California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference

The Pharmalot View Ed Silverman

Here’s how a loophole in a transparency law can distort medical practices

The Pharmalot View Ed Silverman

STAT Plus: This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

The Pharmalot View Ed Silverman

STAT Plus: At $475,000, new cancer drug raises thorny questions about drug pricing — and value

The Pharmalot View Ed Silverman

STAT Plus: Drug makers deserve to be publicly shamed for thwarting competition from generics

The Pharmalot View Ed Silverman

STAT Plus: The art of the deal? Why a money-back guarantee for drugs is a bad idea

The Pharmalot View Ed Silverman

STAT Plus: If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon

The Pharmalot View Ed Silverman

STAT Plus: It’s time to make it legal for Americans to order prescription drugs from abroad

The Pharmalot View Ed Silverman

STAT Plus: US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it

The Pharmalot View Ed Silverman

STAT Plus: The Trump administration could bring down drug prices. But it would take guts

The Pharmalot View Ed Silverman

STAT Plus: Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

The Pharmalot View Ed Silverman

STAT Plus: How a $37,000-a-year medicine sets a good model for drug pricing

The Pharmalot View Ed Silverman

STAT Plus: Here’s one drug safety rule the FDA should enact — quickly

The Pharmalot View Ed Silverman

STAT Plus: Dear Mr. President: Your view of the FDA is misguided. Here’s why

The Pharmalot View Ed Silverman

STAT Plus: Dear Vice President Pence: Stop peddling false hopes to dying patients

The Pharmalot View Ed Silverman

STAT Plus: Pharma trade group vows to review membership criteria, but is this an empty promise?

The Pharmalot View Ed Silverman

STAT Plus: Dear President Trump: Your big idea on drug pricing is half-baked

The Pharmalot View Ed Silverman

STAT Plus: Drug industry ad campaign may be too late to save its reputation

The Pharmalot View Ed Silverman

STAT Plus: Trump is considering a radical to lead FDA. That’s dangerous for public health

The Pharmalot View Ed Silverman

Trump should be good medicine for the pharmaceutical industry. Here’s why

The Pharmalot View Ed Silverman

STAT Plus: Pharma may have defeated Prop 61, but state battles over pricing will continue

The Pharmalot View Ed Silverman

STAT Plus: Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

The Pharmalot View Ed Silverman

STAT Plus: Health officials should reject latest gambit by EpiPen maker to feed at the public trough

The Pharmalot View Ed Silverman

Behind the grandstanding, Congress may have taken a key step to clarifying drug prices

The Pharmalot View Ed Silverman

Allergan CEO looks smart for pledging to rein in prices. But will it make a difference?

The Pharmalot View Ed Silverman

The secretive system for vetting cancer drug use needs an urgent overhaul

The Pharmalot View Ed Silverman

An open letter to Mylan CEO Heather Bresch about EpiPen pricing

The Pharmalot View Ed Silverman

STAT Plus: Laws to shed light on drug pricing strategies probably won’t work